How is an entire patent portfolio valued vs. a single patent?

Value concentrates, overlaps, and interacts. Concentration means most of the total sits in a handful of assets, so precision on the tail buys nothing. Overlap means two patents covering the same product feature do not deliver twice the exclusion value. Interaction runs the other way: a cluster of patents that together fence off a technology can be worth more than its parts, because a competitor cannot design around five coordinated patents the way they design around one.

This is why a credible portfolio valuation costs far less than the per-patent price times the patent count, and why a one-patent methodology scaled naively to three hundred families produces a number nobody should rely on.

An individual patent can be valued in isolation, and sometimes a licensing or sale question calls for exactly that. More often the portfolio is valued as a whole. We start from the products and markets the patents touch: which ones read on shipping products, where the coverage runs deep enough to matter, and how the families reinforce each other. The strongest, most clearly practiced assets get the closest analysis, usually income-method work supported by evidence of use; the rest are weighed for the coverage, optionality, and defensive mass they add to the set rather than appraised one by one.

Scale is part of the value, not just the cost. A broader portfolio generally carries lower risk, because the outcome no longer hinges on a single patent surviving challenge, and it can support a claim on a larger share of a licensee's revenue: a deep position in a technology can justify a royalty on more of the product than a lone patent covering one feature ever could. The deliverable reflects that, showing where the value concentrates, what drives the top assets, and usually a pruning recommendation, since most portfolios we see are paying maintenance fees on assets that no longer earn them.

On the positive side: international family coverage multiplies the markets where exclusion is enforceable, live continuations let an owner write new claims toward where the market went, and sheer defensive mass has cross-licensing value in industries where everyone infringes everyone. On the negative side: assets nearing expiration, exclusive licenses already granted (which can gut transfer value), title or inventorship gaps, and the forward maintenance-fee obligation, which is a real liability stream a buyer will model.

At ipCG, portfolio valuations run on the same published tiers as single-asset work, from about $5,000 for a first-pass to $50,000 and up for transaction-grade analysis, with scope scaling on portfolio size rather than multiplying by it.